Guangdong Zhongsheng Pharmaceutical Co., Ltd.   Report issue

For profit Phase 1
Founded: Guangdong China (1979)
Status: No NME R&D (1979)

Organization Overview

First Clinical Trial
2018
NCT03392779
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Guangdong Zhongsheng Pharmaceutical Co., Ltd. | ZhongSheng BioTech Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Basal Cell (Phase 1)

Carcinoma, Hepatocellular (Phase 1)

Cholangiocarcinoma (Phase 1)

Fatty Liver (Phase 1)

Glioblastoma (Phase 1)

Idiopathic Pulmonary Fibrosis (Phase 1)

Medulloblastoma (Phase 1)

Neuroendocrine Tumors (Phase 1)

Non-alcoholic Fatty Liver Disease (Phase 1)

Pulmonary Fibrosis (Phase 1)

Small Cell Lung Carcinoma (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 6
  • # of Trial APIs: 7